Page last updated: 2024-08-21

fluorobenzenes and Migraine Disorders

fluorobenzenes has been researched along with Migraine Disorders in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (33.33)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (33.33)	24.3611
2020's	1 (33.33)	2.80

Authors

Authors	Studies
Dripps, I; Goadsby, PJ; Holland, PR; Pradhan, A; Saengjaroentham, C; Strother, LC; Sultan Jabir, MR	1
Mitsikostas, DD; Tfelt-Hansen, P	1
Branchek, TA; Calligaro, DO; Flaugh, ME; Gilbert, PJ; Johnson, KW; Kiefer, AD; Mancuso, V; Nelson, DL; Phebus, LA; Van Belle, K; Zgombick, JM	1

Reviews

1 review(s) available for fluorobenzenes and Migraine Disorders

Article	Year
Targeting to 5-HT1F receptor subtype for migraine treatment: lessons from the past, implications for the future. Central nervous system agents in medicinal chemistry, 2012, Volume: 12, Issue:4 Topics: Animals; Benzamides; Carbazoles; Clinical Trials as Topic; Disease Models, Animal; Drug Evaluation, Preclinical; Fatigue; Fluorobenzenes; Humans; Indoles; Migraine Disorders; Models, Neurological; Molecular Targeted Therapy; Nausea; Paresthesia; Pilot Projects; Piperidines; Pyridines; Randomized Controlled Trials as Topic; Receptor, Serotonin, 5-HT1F; Receptors, Serotonin; Serotonin; Serotonin Receptor Agonists; Treatment Outcome; Vertigo	2012

Article

Year

Targeting to 5-HT1F receptor subtype for migraine treatment: lessons from the past, implications for the future.

Central nervous system agents in medicinal chemistry, 2012, Volume: 12, Issue:4

Topics: Animals; Benzamides; Carbazoles; Clinical Trials as Topic; Disease Models, Animal; Drug Evaluation, Preclinical; Fatigue; Fluorobenzenes; Humans; Indoles; Migraine Disorders; Models, Neurological; Molecular Targeted Therapy; Nausea; Paresthesia; Pilot Projects; Piperidines; Pyridines; Randomized Controlled Trials as Topic; Receptor, Serotonin, 5-HT1F; Receptors, Serotonin; Serotonin; Serotonin Receptor Agonists; Treatment Outcome; Vertigo

2012

Other Studies

2 other study(ies) available for fluorobenzenes and Migraine Disorders

Article	Year
Differential medication overuse risk of novel anti-migraine therapeutics. Brain : a journal of neurology, 2020, 09-01, Volume: 143, Issue:9 Topics: Animals; Calcitonin Gene-Related Peptide Receptor Antagonists; Carbazoles; Fluorobenzenes; Headache Disorders, Secondary; Male; Mice; Mice, Inbred C57BL; Migraine Disorders; Pain Measurement; Piperazines; Quinazolines; Receptor, Serotonin, 5-HT1F; Receptors, Calcitonin Gene-Related Peptide; Receptors, Serotonin; Risk Factors	2020
Characterization of LY344864 as a pharmacological tool to study 5-HT1F receptors: binding affinities, brain penetration and activity in the neurogenic dural inflammation model of migraine. Life sciences, 1997, Volume: 61, Issue:21 Topics: Animals; Brain; Carbazoles; Disease Models, Animal; Dura Mater; Fluorobenzenes; Humans; Inflammation; Male; Migraine Disorders; Protein Binding; Rats; Rats, Inbred F344; Receptor, Serotonin, 5-HT1F; Receptors, Serotonin; Recombinant Proteins; Serotonin Receptor Agonists	1997

Article

Year

Differential medication overuse risk of novel anti-migraine therapeutics.

Brain : a journal of neurology, 2020, 09-01, Volume: 143, Issue:9

Topics: Animals; Calcitonin Gene-Related Peptide Receptor Antagonists; Carbazoles; Fluorobenzenes; Headache Disorders, Secondary; Male; Mice; Mice, Inbred C57BL; Migraine Disorders; Pain Measurement; Piperazines; Quinazolines; Receptor, Serotonin, 5-HT1F; Receptors, Calcitonin Gene-Related Peptide; Receptors, Serotonin; Risk Factors

2020

Characterization of LY344864 as a pharmacological tool to study 5-HT1F receptors: binding affinities, brain penetration and activity in the neurogenic dural inflammation model of migraine.

Life sciences, 1997, Volume: 61, Issue:21

Topics: Animals; Brain; Carbazoles; Disease Models, Animal; Dura Mater; Fluorobenzenes; Humans; Inflammation; Male; Migraine Disorders; Protein Binding; Rats; Rats, Inbred F344; Receptor, Serotonin, 5-HT1F; Receptors, Serotonin; Recombinant Proteins; Serotonin Receptor Agonists

1997